Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ENDRA Life Sciences ( (NDRA) ) has issued an update.
On March 25, 2026, ENDRA Life Sciences said its board had begun a review of strategic alternatives to maximize shareholder value, retaining Lucid Capital Management as financial advisor and K&L Gates as legal counsel. The board will consider options including strategic investments, mergers, business combinations, collaborations, asset sales, or a potential sale or merger of the company, while ENDRA continues to execute on its core TAEUS business.
As part of this shift in strategy, ENDRA reduced its workforce on March 19, 2026, to cut cash expenditures and extend its operational runway, a move that will result in about $51,000 in pre-tax severance charges recognized in the first quarter of 2026. The actions signal a recalibration of operations and capital allocation as the company seeks a sustainable path forward in a challenging healthcare technology and capital markets environment.
The most recent analyst rating on (NDRA) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on ENDRA Life Sciences stock, see the NDRA Stock Forecast page.
Spark’s Take on NDRA Stock
According to Spark, TipRanks’ AI Analyst, NDRA is a Neutral.
NDRA scores low primarily due to very weak financial performance (no reported revenue, persistent losses, significant cash burn, and reduced equity cushion). Technical indicators are also bearish with the price below key moving averages and a negative MACD, partially offset by near-oversold stochastic conditions. Valuation provides limited support because negative earnings make the P/E not meaningful and no dividend yield is provided.
To see Spark’s full report on NDRA stock, click here.
More about ENDRA Life Sciences
ENDRA Life Sciences Inc. is a medical technology company developing Thermo Acoustic Enhanced Ultrasound (TAEUS), a thermoacoustic biomarker imaging platform designed to assess tissue fat content and monitor tissue ablation at the point of care. The technology is currently focused on measuring liver fat to help assess and monitor steatotic liver disease and related chronic liver conditions, a large global market with limited practical diagnostic tools.
Average Trading Volume: 108,151
Technical Sentiment Signal: Sell
Current Market Cap: $4.04M
See more data about NDRA stock on TipRanks’ Stock Analysis page.